Back to search

Duquesne

Theoretical Aspects of Designing New Vaccines for Breast Cancer: Docking Studies of Peptide/HLA-A2.1 Complexes

Abstract

dc:description.abstract

HER2/neu is a transmembrane glycoprotein that is overexpressed in many tumors, including ovarian and breast cancers. The HER2/neu peptide IISAVVGIL (GP2) is recognized by tumor-specific cytotoxic T lymphocytes in the context of human class I major histocompatibility complex (MHC) HLA-A2.1. One limiting-factor for using GP2 as a tumor vaccine is its poor affinity for HLA-A2.1, even though it has the correct peptide-binding motif. The research aims are to develop an accurate docking method for the binding of GP2 to HLA-A2.1, to understand the molecular forces that give rise to strong binding, and to predict mutations that lead to new tumor vaccines. AutoDock and GOLD have been used for docking calculations. The binding free energies from AutoDock correlate qualitatively with experiment. The docked structures for 14 ligands from Autodock3 are in good agreement with experiment. However, the ligands are not fully flexible. GOLD allowed full flexibility to reproduce experimental GP2 structure.

Degree

thesis:*
Name thesis:degree_name
MS
Level thesis:degree_level
Immediate Access
Discipline thesis:degree_discipline
Chemistry and Biochemistry

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kucukkal, Tugba
Contributors dc:contributor
  • Jeffrey D. Evanseck
  • Charles T. Dameron
  • David W. Seybert
  • Jeffry D. Madura

Subjects

dc:subject × 1

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/786

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Kucukkal, Tugba. Theoretical Aspects of Designing New Vaccines for Breast Cancer: Docking Studies of Peptide/HLA-A2.1 Complexes. Immediate Access thesis, https://dsc.duq.edu/etd/786